報價延遲最少15分鐘:2025/01/21 08:56 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
-- 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.69/-1.26
|
|
企業價值
457.91M
|
| 資產負債 |
|
每股賬面淨值
2.69
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
39.30M
|
|
每股收益
1.45
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 08:56 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market. |